Jaimiess NDC 70700-206

NDC codes

FDA NDC Directory

Product NDC (as listed)70700-206Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70700-0206Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70700-206-93	70700020693	2 POUCH in 1 CARTON (70700-206-93) / 1 BLISTER PACK in 1 POUCH (70700-206-87) / 1 KIT in 1 BLISTER PACKMarketed from Jan 29, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Jaimiess
Generic name (nonproprietary): levonorgestrel and ethinyl estradiol and ethinyl estradiol tablets
Dosage form: Kit
Labeler: Xiromed LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 200492
Marketing start: Jan 29, 2025
Listing expires: Dec 31, 2026
Identifiers: Product ID 70700-206_f5210b99-c55c-c01d-1e7b-9d92985f66faSPL ID f5210b99-c55c-c01d-1e7b-9d92985f66faSPL set ID c094e6de-f1e9-9594-43f3-de1c1bb49bdbRxCUI 238019, 248310, 749761, 2001751UPC 0370700206935

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N470700020693 followed by a unit qualifier and the quantity

Package 70700-0206-93. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 25, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

Jaimiess is indicated for use by females of reproductive potential to prevent pregnancy. Jaimiess is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)